RxDoctor Payments Data

Sandra Anderson

Psychiatric/Mental Health · Pittsburg, KSNPI 1538133152

Payments from drug & device makers

$714in general payments, 2019–2025

Across 41 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$223
  • AbbVie$114
  • Alkermes, Inc.$88
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$77
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$47
  • E.r. Squibb & Sons, L.L.C.$34
  • plus $132 from 6 others

What the payments were for

  • Food & beverage$56179%
  • Education$15321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$714 in reported general payments places this provider in the 55th percentile of 404 psychiatric/mental health providers in Kansas.

See all psychiatric/mental health providers in Kansas

Medicare billing

Part B allowed, 2024
$4,515
Medicare patients
33
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate85$295,662
IngrezzaValbenazine Tosylate21$168,028
Austedo XrDeutetrabenazine20$150,519
RexultiBrexpiprazole41$75,244
VraylarCariprazine Hcl57$73,859
Abilify MaintenaAripiprazole12$36,082
Paliperidone ErPaliperidone108$21,681
TrintellixVortioxetine Hydrobromide21$11,200
Aripiprazole143$7,249
Vilazodone Hcl74$5,946
Lurasidone Hcl37$4,089
Olanzapine210$3,453
Ziprasidone Hcl22$3,359
Oxcarbazepine45$3,104
Quetiapine Fumarate160$3,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$15$168,02821 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Loxapine$223$151,02233 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$33$111,32653 claims
AbbVieVraylar$114$73,85957 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 404 psychiatric/mental health providers in Kansas.

Other psychiatric/mental health in Pittsburg

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →